Podcasts about GIP

Willkommen im Herbst, liebe Leute, und willkommen zu einem neuen EvidenzUpdate. Vorsicht, heute kommt es ganz dicke. Wir nehmen uns eine aus mehreren Gründen interessante Arbeit vor: einen Head-to-Head-Vergleich, der die GLP-1-Analoga Semaglutid und Tirzepatid (das als Twinkretin auch an GIP bindet) untersucht bei Menschen mit kardiometabolischer Herzinsuffizienz (konkret HFpEF).

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

In this episode of The Health Revival Show, Liz & Becca break down Retatrutide—a new GLP-1, GIP, and glucagon receptor agonist that's making waves in the functional health and metabolic space. Is it really “Ozempic on steroids”? They cut through the hype and bring the context no one's talking about—the importance of muscle preservation, insulin sensitivity, thyroid health, and how to use these tools responsibly (or if at all). Whether you're considering peptides or just curious about this next-gen weight loss compound, this episode delivers the no-BS truth.

In this episode, I share some thoughts on managing hunger.. both when you're in a calorie deficit and in everyday life.We'll talk about what drives hunger (like leptin, ghrelin, and even GLP-1/GIP meds), why it ramps up during dieting, and simple ways to keep it in check through food choices, lifestyle habits, and mindset shifts.If hunger has been making things harder than they need to be, this one's for you.Where to find me:IG: @lukesmithrdCheck out my website HEREFill out a 1:1 coaching application HERE

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

Welcome back to Ozempic Weightloss Unlocked, the show that brings listeners the most current news, research, and perspectives on Ozempic, the medication that has transformed weight loss conversations everywhere.Ozempic, generically known as semaglutide, was originally approved for type two diabetes by the FDA in 2017. Its follow-up, Wegovy, hit the market in 2021 explicitly for chronic weight management. Both drugs belong to a class called glucagon-like peptide-one receptor agonists. These medications work by mimicking a naturally occurring hormone that helps the body regulate blood sugar after meals while also reducing appetite by slowing the digestive process. Many patients taking Ozempic weekly have seen impressive reductions in body weight—up to 16 percent, according to data highlighted by the American Journal of Managed Care.The popularity of Ozempic exploded when its weight loss effects were amplified on social media and through celebrity endorsements. Demand surged, and global interest grew as more people sought medical solutions outside of diet and exercise alone. But Ozempic is not just hype—it's backed by multiple clinical trials and growing medical consensus, though not without debate.Researchers continue to push the boundaries, and major updates are underway. According to Fox News Digital and the Times of India, scientists at Tufts University have developed a next-generation experimental drug aimed at delivering weight loss of up to thirty percent—nearly matching surgical outcomes but without the operation. This new compound works across four hormone pathways: GLP-1, GIP, glucagon, and peptide YY, aiming to deliver robust weight loss with fewer side effects like nausea and muscle loss. The “quadruple-action” drug is still in early preclinical stages, tested only in cells—not yet in humans or animals—but represents a bold step towards more personalized, gentle, and sustainable weight management therapies.For now, single-hormone agents like Ozempic remain widely prescribed. Experts urge those on GLP-1 medications to partner closely with their clinicians, focusing on daily protein, hydration, and resistance training to mitigate risks such as muscle loss and malnutrition. Nutritional support is key, as well as regular follow-ups.Alongside medical progress, litigation and warnings continue to surface. The Lawsuit Information Center reports that thousands of claimants have entered into multidistrict litigation over Ozempic and similar drugs, citing side effects like gastroparesis, or stomach paralysis, and rare forms of vision loss including neovascular age-related macular degeneration and optic neuropathy. A 2025 study out of the University of Toronto found semaglutide users twice as likely to develop macular degeneration compared to others—a small risk, but real and statistically significant. Another concern comes from JAMA Otolaryngology–Head & Neck Surgery, showing a possible increased risk of thyroid cancer among GLP-1 agonist users. The defense argues that many of these side effects are rare, and some findings may be linked to increased medical surveillance, rather than the drug itself. Physicians and patients are encouraged to weigh these risks alongside the benefits and always discuss options thoroughly before starting treatment.As for what comes next, listeners should keep an eye on innovations underway: oral drugs like orforglipron, combination therapies such as CagriSema, and monthly injectables from major firms—all targeting more effective weight loss with easier dosing and fewer downsides. Tirzepatide, branded as Zepbound, is currently considered one of the most potent with trial data showing up to twenty-one percent body weight loss.The obesity epidemic is far from solved, but the next wave of treatments could make weight loss less about suffering and more about smart science. Whether listeners are considering Ozempic, awaiting newer options, or just tuning in for updates, the biggest takeaway is this: work with a trusted healthcare provider, stay informed about the latest findings, and balance medication with healthy lifestyle habits.Thank you for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe and share. This has been a Quiet Please production—for more, check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic continues to dominate news cycles in September 2025, with both scientific developments and celebrity stories capturing headlines. Designed originally for the management of type two diabetes, the medication and others like it are known as GLP-1 receptor agonists, which help regulate blood sugar and can reduce appetite, making them highly effective for weight loss. In the past week, researchers at Tufts University have made waves by unveiling a new experimental “quadruple-action” drug they hope will surpass Ozempic's results. As reported by Fox News and the Times of India, this candidate targets not just the GLP-1 hormone but also GIP, glucagon, and peptide YY, with the goal of matching the 30 percent weight loss typically seen in bariatric surgery, all while minimizing side effects. This is an ambitious aim, given that current drugs often bring unwanted symptoms such as nausea, muscle loss, and weight regain. However, the new drug has only been tested in cell cultures so far and will need years of animal and human trials before it becomes widely available.Ozempic itself remains widely prescribed for people with obesity and continues to be in the spotlight due to reports of its effectiveness paired with manageable side effects when overseen by experienced physicians. Still, the risks of muscle loss and malnutrition require users to balance medication with a disciplined regimen of nutrition and resistance training. The cultural conversation about Ozempic, however, has recently shifted from strictly medical debates to the realm of celebrity influence, especially as Oprah Winfrey's transformative journey with the drug has been in the headlines nearly every day this week.Oprah, known for her openness about her decades-long struggle with weight, took center stage at Ralph Lauren's New York Fashion Week show just days ago, making headlines for her dramatic weight loss. According to Media Take Out and Radar Online, Oprah was seen in a fitted and chic ensemble that highlighted what insiders claim is a forty pound reduction, bringing her to a size four, her smallest size since the nineteen eighties. Paparazzi photos were widely circulated, and feedback was immediate and intense, with some admirers celebrating her healthy, radiant appearance and others fueling speculation about her use of Ozempic or related medications. While Oprah herself admitted publicly last year to using Ozempic, describing the medication as “a gift, not something to hide behind” and framing it as a means of managing lifelong struggles, she has not given detailed comment in the last seven days. Her most recent Instagram posts, promoting her latest book club selection, prompted such a strong response that she turned off the comments, signaling just how sensitive and intense the public reaction has been.The broader Ozempic conversation in the last week has also included updates on ongoing litigation in the United States, as courts and lawyers debate whether Novo Nordisk, the drug's manufacturer, adequately warned users of risks such as gastroparesis and vision problems. As reported by the Lawsuit Information Center, over two thousand lawsuits have been consolidated in federal courts, focusing on both gastrointestinal symptoms and rare cases of vision loss that some users attribute to the medication. While most users experience positive results, the growing number of legal claims highlights the demand for more transparent labeling and comprehensive risk evaluation.Despite these issues, medical professionals continue to recommend GLP-1 drugs like Ozempic for patients who struggle with obesity and for whom other approaches have failed, emphasizing the need for individualized care. Doctors urge patients to pair medications with sufficient protein intake, hydration, strength training, and quality sleep to prevent muscle and bone loss. The Tufts University innovation, still in early stages, reflects a drive toward safer, more personalized treatments that may eventually sidestep the most common drawbacks of current medications.For listeners who follow celebrity news, Oprah Winfrey's story remains one of the most visible testaments to the power and controversy of Ozempic. Her experience—now widely discussed and often scrutinized—demonstrates how medical advances can intersect with cultural norms, personal empowerment, and public debate. In the words Oprah shared during her journey, the availability of credible, medically approved options can bring relief and a fresh sense of hope to people who have lived with stigma for much of their lives.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover the shocking assassination of Charlie Kirk, Russian drones breaching NATO airspace, Trump's war on Venezuela's cartels, Mexico's tariff fight with China, a pharmaceutical victory in Tennessee, and new revelations in the 9/11 families' lawsuit against Saudi Arabia. From political violence at home to dangerous escalations abroad, today's brief carries heavy news on a day of prayer and remembrance.   Charlie Kirk Assassinated in Utah: The 31-year-old Turning Point USA founder was gunned down while speaking at Utah Valley University. President Trump called him “a martyr for truth and freedom” and ordered flags at half-staff. Video shows a sniper shot to the neck from a rooftop as Kirk addressed thousands of students. MSNBC sparked outrage with coverage that suggested Kirk's “awful words” made his death inevitable. Bryan warns, “The seal has now been broken: if you make those arguments or say those words, you're fair game too.”   Russian Drones Violate Polish Airspace: NATO confirms 19 Russian drones flew over 150 miles into Poland, with several shot down by Dutch and Polish jets. Bryan cautions that even an accident could spark a “Gulf of Tonkin–like incident” dragging NATO into direct war with Moscow.   Trump Escalates War on Venezuela's Cartels: After U.S. forces sank a drug boat killing 11, critics accuse Trump of overstepping presidential authority. War Secretary Pete Hegseth countered: “This strike sent a clear message: If you traffic drugs toward our shores, the United States military will stop you cold.”   Mexico Tariffs Chinese Imports: President Claudia Sheinbaum hikes tariffs on Chinese cars and textiles to 50 percent, aiming to shield Mexican workers and appease Trump's demands to close tariff loopholes. Bryan notes this could undercut Beijing's backdoor into U.S. markets.   Saving U.S. Antibiotics in Tennessee: Trump brokers a deal forcing Walmart and McKesson to buy amoxicillin from Bristol, Tennessee, rescuing America's last antibiotic factory from collapse. “Don't bet against America,” Bryan says, “because with leadership that actually loves this country, we will win.”   9/11 Families' Lawsuit Against Saudi Arabia Advances: A New York judge allows families to pursue claims that Saudi intel officers Omar al-Bayoumi and Fahad al-Thumairy aided hijackers. ProPublica reports al-Bayoumi was a Saudi intel asset in the U.S. coordinating with the GIP. Bryan calls for Trump to declassify CIA files: “It's time for some sunlight on what did or didn't happen that horrific day.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/TWR and use code TWR at checkout.     Keywords: Charlie Kirk assassination Utah, Trump martyr for truth, MSNBC Charlie Kirk coverage, Russian drones Poland NATO, Trump Venezuela drug cartels strike, Pete Hegseth drug cartels al Qaeda, Mexico tariffs Chinese imports Sheinbaum, Trump tariff war China backdoor, U.S. antibiotics Bristol Tennessee amoxicillin, Walmart McKesson Trump drug deal, 9/11 families lawsuit Saudi Arabia, Omar al-Bayoumi Saudi intel, Fahad al-Thumairy Saudi cleric, CIA Saudi 9/11 declassification

Ozempic continues to lead weight loss headlines this week, as researchers and public figures weigh in on its cultural significance, effectiveness, risks, and the next generation of weight loss solutions. Recent medical reporting indicates an intensifying push for innovation in pharmaceutical weight management. At Tufts University, scientists have crafted a new experimental drug that aspires to surpass Ozempic by targeting four distinct hormones—GLP-1, GIP, glucagon, and peptide YY—rather than just GLP-1 or GIP. This novel approach aims not only for a greater degree of weight loss, with laboratory targets up to thirty percent, but also promises to mitigate the unpleasant side effects often experienced with existing drugs like Ozempic and Wegovy. If successful, the results would rival those of bariatric surgery without surgical intervention. The new compound is engineered for broader metabolic impact, supporting appetite control, minimizing nausea, balancing energy, and optimizing fat burning. However, the medication is still in early development, with laboratory and animal trials ahead before any human use or clinical rollout. Researchers and doctors alike continue to emphasize that while single-agent GLP-1 drugs such as Ozempic are currently effective for most patients, they can cause notable muscle loss and malnutrition if not managed with proper nutrition and strength training. There is ongoing conversation among health professionals about combining these medicines with healthy lifestyle practices in order to minimize risks and sustain benefits.Ozempic's cultural relevance has also been amplified by celebrities, none more so than Oprah Winfrey, who continues to be a focal point in discussions about medically assisted weight loss. Within the past week, online platforms have highlighted Oprah's increasingly slim appearance—she herself has attributed the transformation in part to the use of GLP-1 medications following decades of struggle with her weight. On social media and in a recent podcast episode, Oprah reflected on her realization that biology, not just willpower, governs much of one's weight outcomes. She described how GLP-1 medications quiet her mental preoccupation with food in a way that she once thought only belonged to thinner people. For Oprah, naming her medication use was an act of transparency and self-acceptance. She declared she is finished with the stigma and shame often attached to weight loss and pharmaceutical intervention, especially after years of public scrutiny and self-blame. In interviews, she further explained that using Ozempic as a tool—not a sole solution—helped her decouple her sense of self-worth from her body size. Oprah continues to advocate for holistic weight management routines, which include daily movement, mindful eating, adequate sleep, and emotionally supportive practices. Although she is no longer officially involved with Weight Watchers, she maintains that community, accountability, and compassionate health habits remain critical for achieving and sustaining wellness.As Ozempic's popularity has soared, so have concerns and legal disputes. This week, legal updates show ongoing litigation over side effects such as gastroparesis—a condition that slows stomach emptying—while the United States Food and Drug Administration tightens its regulations on raw ingredients for GLP-1 medications, aiming to prevent the market influx of counterfeit or unsafe drugs. Medical authorities remain cautious, reminding listeners that all medications carry inherent risks, and full transparency around side effects is essential for safe prescribing.Additionally, new scientific research out of Australia this week raised red flags about women of reproductive age using GLP-1 receptor agonists like Ozempic for weight loss without considering reproductive health consequences. Many young women starting these medications do not use effective contraception, despite well-documented risks to pregnancy outcomes, highlighting the need for better clinical counseling as uptake continues to surge.In sum, the past week reveals a turning point for both Ozempic and the broader landscape of medical weight loss. The next generation of treatments is taking shape in the lab, even as current drugs spark both hope and concern. Public voices like Oprah Winfrey are helping normalize the use of medical tools while championing compassion and accountability, and ongoing reviews of risks are prompting regulatory reform. As science, culture, and policy evolve side by side, listeners are witnessing a critical shift in attitudes toward health, body image, and the future of weight management.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Per ben quattro volte il GIP di Reggio Calabria respinge le richieste di archiviazione della procura, chiedendo nuove indagini ed esami, dando vita così ad una guerra di perizie tra la procura e la famiglia di Fausto. Strane macchie di sangue, autopsia svolta dopo tre anni dalla morte e un insieme di dettagli che stonano con la ricostruzione suicidaria. La verità sembra a portata di mano ma ogni giorno sembra anche allontanarsi sempre di più mentre la famiglia, a distanza di nove anni, sta ancora lottando in cerca di verità e giustizia per il proprio figlio.See omnystudio.com/listener for privacy information.

Today we're diving into a topic that a lot of people struggle with quietly but don't always feel comfortable talking about: food anxiety. And if you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Maybe you've felt nervous about going to a party because you weren't sure what kind of food would be there. Or maybe you've found yourself planning your entire day around what you'll eat and how to control it. Perhaps you've even finished a meal only to have guilt set in right away. That's what food anxiety looks like—and you are definitely not alone. Today we're going to talk about what food anxiety actually is, why it shows up, what you can do to calm it, and even how some of the newest medications—things like GLP-1s and dual GIP/GLP-1s—may actually help by quieting some of the mental “food noise.” What is food anxiety? At its core, food anxiety is stress or fear around eating. And the thing is, it doesn't look the same for everyone. For one person, it might show up as constantly worrying they'll overeat. For another, it's that lingering guilt after eating something they feel they “shouldn't have.” And sometimes it's more subtle than that—like a constant hum in the background of your mind where you're thinking about food all day, even when you're not hungry. I often describe it like having a radio station in your brain that's tuned into “food talk.” Sometimes it's background noise, sometimes it's blaring, but either way, it's draining. And over time, that stress around eating chips away at both your mental and physical health. Why does food anxiety happen? So why does this happen in the first place? A big part of it is the culture we live in. For decades, we've been bombarded with messages that carbs are bad, fat is bad, sugar is the enemy—and the list keeps changing. That constant labeling of food as “good” or “bad” teaches us to feel guilty when we eat the so-called wrong thing. For others, food anxiety starts when they get a medical diagnosis. If you've been told you have diabetes, heart disease, or that you need to lose weight for health reasons, suddenly every single bite can feel like a math problem. You're not just eating—you're calculating, you're worrying, you're second-guessing. And then there's the way dieting itself messes with our natural signals. When we spend years restricting, counting, and controlling, we often lose touch with our body's hunger and fullness cues. Instead of trusting how we feel, we rely on rigid rules. And when those rules get broken, the anxiety hits hard. And finally, we can't ignore biology. Food, especially highly processed food, lights up reward pathways in the brain. For some people, those signals are incredibly strong—stronger than for others. That means more cravings, more urges, and unfortunately, more guilt when they give in. What can you do about food anxiety behaviorally? Now, here's the good news. There are things you can do to reduce food anxiety, and you don't need to overhaul your entire life to start seeing changes. One of the simplest but most powerful tools is mindful eating. And I know that phrase gets thrown around a lot. But at its heart, mindful eating just means slowing down.  It means actually tasting your food, noticing the textures, and checking in with how your body feels. When you slow down enough to notice satisfaction, you're much more likely to stop eating when you're comfortable instead of stuffed—and that takes a lot of the stress out of the meal. Another shift that helps tremendously is dropping the “good” and “bad” food labels. Health isn't decided by one cookie, just like it isn't guaranteed by one salad. What matters is your overall pattern, week by week, month by month. When you start to see food as neutral—as fuel, as enjoyment, as part of life—it loosens the grip of guilt and allows you to be more flexible. And speaking of flexibility, having a loose structure around meals can be calming. Instead of rigid dieting rules, like “I can never eat after 7 p.m.,” focus on balance. A meal that has some protein, some fiber, and a little healthy fat is naturally stabilizing. It helps keep blood sugar steady, which means fewer spikes and fewer crashes. And when your body feels stable, your brain feels calmer, too. It's also worth paying attention to your personal triggers. For some people, weekly weigh-ins, keeping a food log, or using a nutrition app can be helpful. But for others, they actually fuel the anxiety. If you notice those things making you more stressed rather than less, it's okay to step away from them. You can still eat intentionally without logging every single bite. And while we are on the subject of personal triggers like daily or weekly weigh-ins, I want to talk about this a bit more. It's really important to remember, your body weight naturally fluctuates from day to day. Daily weight changes are completely normal and can happen for a bunch of reasons.  Your body might hold onto water from salty foods, hormones, or just changes in hydration. What you've eaten recently can also temporarily add weight, and when you eat carbohydrates, your muscles store them along with water, which can make the scale go up a bit. For women, hormonal changes during the menstrual cycle can cause water retention that shows on the scale as well. On top of all that, if you've been exercising more, you might be building muscle even while losing fat. Because muscle is denser than fat, the scale might not move—or could even go up slightly—while your body is actually getting leaner and stronger. Because of these normal variations, seeing a slightly higher number on the scale one day can feel discouraging—even if you're making great progress. Instead of focusing on daily fluctuations, a better approach is to look at your net overall trend over a month. Tracking the weekly or monthly average gives you a more accurate picture of real progress and helps reduce stress or obsession with the number on the scale And lastly, support makes a big difference. Whether that's working with a dietitian, talking with a therapist, or joining a group, sometimes having someone else in your corner makes it easier to change both your habits and the way you think about food. Where medications may help: GLP-1s and dual GIP/GLP-1s Now let's shift gears for a moment, because in the past few years, there's been an exciting development in how we treat weight and appetite. Medications like GLP-1 receptor agonists—semaglutide is one example—and the newer dual GIP/GLP-1 agonists, like tirzepatide, have been game changers. So what do they actually do? GLP-1s mimic a natural hormone your gut makes after you eat. That hormone tells your brain, “Hey, you're full.” It also slows down how quickly food leaves your stomach and helps keep you fuller, longer. They also cause your pancreas to release insulin when there's too much sugar from food in your bloodstream. This lowers your blood sugar and helps your cells use glucose (sugar from the food you've eaten). This is helpful because extra sugar your cells don't use for energy is stored as fat, which is why high blood sugar can cause weight gain.  The dual GIP/GLP-1s do all of that, plus they act on another hormone called GIP, GIP improves how your body uses sugar AND fat (storing less of both by breaking them down to use for energy). Now, here's where it gets fascinating for food anxiety. People who take these medications often report that the “food noise” in their head finally quiets down. Instead of thinking about food all day, the volume on that radio station turns way down. Meals feel more manageable. A normal portion actually feels satisfying. And for many, that overwhelming urge to snack or binge just isn't there anymore. When your hunger cues are more predictable and less intense, you don't feel like you're constantly fighting your own body. That alone can dramatically reduce the anxiety around eating. And by calming the physical side—the cravings, the urges—it gives you more space to work on the mental and emotional side of eating without feeling like you're swimming upstream. Of course, these medications aren't a magic fix. They don't erase years of learned guilt or change the culture we live in. But they can be powerful tools, especially when paired with mindful eating practices and professional support. My Final Thoughts If you take one thing away from this episode, let it be this: food anxiety is real. It's not about weakness or lack of willpower. It's shaped by culture, by biology, by personal history—and it can be incredibly challenging. But there are ways to reduce it. Slowing down and being more mindful at meals, letting go of the “good food versus bad food” mindset, building flexible eating habits, and getting support are all steps in the right direction. And for some, medications like GLP-1s or dual GIP/GLP-1s can make the process easier by quieting the biological noise that drives anxiety in the first place. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend and please remember you're not alone. Many people struggle with food anxiety, and there is nothing wrong with reaching out for help—whether that's behavioral support, medical treatment, or both. Until next time, be well, and as always, have a happy, healthy week.  

Episode 311 showcases our hosts Dr Jake Sloane & David Segal. In our 'What's trending in Aesthetics?' episodes we discuss popular topics doing the rounds on social media, issues being debated in injector forums or items showcased on the news. We'll cover controversies, big stories and themes that have got injectors and our industry talking. In Chapter 14 our hosts Dr Jake and David explore: the global rise in the use of GLP-1 medications the impact of the 'Trump tariffs' with a huge price hike of Mounjaro (GLP-1/GIP medicine) in the UK - and the implications on the pricing of aesthetic products in the future Kris Jenner's recent facelift and whether not looking your age is the new 'normal' a new on label indication for Botox (platysmal bands of the neck) and why injectors can't afford to ignore this region 00:00 Introduction to Inside Aesthetics 00:47 Welcome to the New Podcast Studio 01:29 Upcoming Conferences and Events 06:26 Exploring GLP-1: The Wonder Drug for Weight Loss 10:28 The Impact of GLP-1 on Aesthetic Practices 21:45 Price Hike in Weight Loss Drugs 23:42 Discussing Botox Price Hike Concerns 24:16 Understanding Gross Margins in Business 24:54 Promoting Our Patreon and Resources 25:17 Price Discrepancies in Pharmaceuticals 26:46 Celebrity Facelifts: The Case of Kris Jenner 28:05 Defining 'Natural' in Cosmetic Surgery 31:25 Combination Treatments for Best Results 37:35 New Trends in Botox Indications 38:36 Improving Consultation Processes 45:10 Concluding Remarks and Contact Information   CLICK HERE TO JOIN OUR PATREON FOR ON DEMAND EDUCATION & SUPPORT CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST JOIN OUR LISTENER WHATSAPP GROUP & SEND US YOUR COMMENTS, SUGGESTIONS OR JUST SAY HI! CONTACT US  

Liver, Lipids, and the Left Ventricle

Voor de seizoensfinale en de 100ste aflevering in Nederland (JA JA MENSEN) blijven we in het Fochteloërveen want de koek is nog lang niet op. Gip heeft nog nooit echt goed een slangenarend gezien dus dat is de doelsoort. Maar ook de wielewaal is weer in het land en het gejodel klinkt al uit de bomen. Het zien is alleen een tweede bij deze vogel. Daarnaast is het lievelingsvogeltje van Arjan ook aanwezig; het paapje. Kortom, het wordt een heerlijke vogeldag vol met verassingen.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

We begin Adventure August by bringing you something from the past and we are MANIC! A visit from our very own lost girl had us bangerang as little hair, big teeth Tink gets swole, we consider the origin of bar eggs, lil' Amber Scott's lack of link, a check being a check and a fart being a fart and granny Wendy being a FREAK. Her and Toodles? Girl, no - Girl, yes! Don't be stingy, get dusty for PeterGet yer ship and GIP! It's Hook, this week on Doom Generation! Support this podcast at patreon.com/doomgeneration

Het lijk net een titel van een spannend kinderboek: De Moerasvogels van het Tuschenwater. Een vogel die al lang op het verlanglijstje van Gip staat en gek genoeg óók op die van Arjan, maar dan op de zelf-ontdeklijst. De grote karekiet. Deze vogel lijkt, het zal je niet verbazen, redelijk veel op zijn kleinere broertje, maar dan, hou je vast, groter. Natuurlijk is dit vloeken in de kerk volgens Arjan en heeft hij nog tal van kenmerken die anders zijn als je goed kijkt. Maar oke, voor de beginnende vogelaar kan je rustig beginnen met het feit dat 'ie groter is. Wél een stuk zeldzamer en daar doe je het voor lieve mensen. Althans Arjan dan. ;) Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright unpack the latest breakthroughs in metabolic medications and why individual biology requires personalized treatment. Dr. Cooper explains how modern therapies for metabolic dysfunction go far beyond the old “one pill fixes all” approach. Discover how hormone-based medications like GLP-1 agonists are changing obesity and diabetes care, why medication response can differ drastically between individuals, and what the future holds for tailored metabolic treatments. You'll come away with a clearer understanding of why effective weight management isn't just about diet or willpower—it's about precision medicine.Key Takeaways:Metabolic dysfunction is a complex, multi-hormonal disease; no single medication will work for everyone.New therapies, including dual and triple hormone agonists (like GLP-1, GIP, and amylin analogs), offer synergistic and individualized effects.Clinical observation shows that increasing doses or the “latest” medication doesn't guarantee better results—some people may even find that their progress disappears after increasing to maximal doses.Lab markers (like ghrelin and leptin) could help personalize treatment, but cost and availability limit widespread testing.Concerns about muscle loss with GLP-1 drugs are common, but clinically, the risk mostly depends on nutrition, strength routines and muscle mass at baseline.Accessibility and cost remain barriers; new small-molecule drugs may improve affordability in the near future.Personal Stories & Practical Advice:Andrea relates how understanding her true metabolic issues, rather than just dieting, led to sustainable health changes.Dr. Cooper describes her clinic's approach to measuring body composition and tracking lean mass to avoid unwanted muscle loss.Listeners are encouraged to work with knowledgeable providers, beware of “one size fits all” narratives, and stay hopeful as newer, more effective treatments emerge.Resources from the episode:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org ordr.c@fatsciencepodcast.com.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to succeed” in arguing that its overhaul of HHS is “lawful.” Meanwhile, FDA Commissioner Marty Makary floated policy changes for the agency, including a proposal to lower prescription drug user fees for the next iteration of the program, and one to offer speedier reviews to companies willing to lower the cost of their drugs.  Last week, the regulator opened its cache of complete response letters (CRLs), offering transparency into the rationale behind more than 200 recent rejections for ultimately approved therapies, including those for Eli Lilly's Alzheimer's drug Kisunla and Sarepta's Duchenne muscular dystrophy (DMD) treatment Vyondys 53. The FDA did not, however, release the CRLs for two new rejections: those of therapies from Ultragenyx and Capricor Therapeutics in Sanfilippo syndrome type A and cardiomyopathy associated with DMD, respectively. It was an especially rough week for Ultragenyx, which also, along with partner Mereo BioPharma, released seemingly negative Phase II/III data for their osteogenesis imperfecta therapy.  On a more positive note, two bustling therapeutic spaces continue to see positive data. In obesity, Hengrui Pharma's Kailera Therapeutics–partnered dual GLP-1/GIP receptor agonist elicited 17.7% average weight loss in a pivotal Chinese trial. And the psychedelic therapeutics space is again generating excitement with two recent positive readouts in treatment-resistant depression. BioSpace took a deep dive into the market reaction to these readouts for Compass Pathways and Beckley Psytech and atai Life Sciences, and what exactly investors are looking for in a successful psychedelic therapy.  Finally, we examine the progress of AI biotech unicorns and kick off our series on women in biopharma with profiles on Mayo Venture Partner Audrey Greenberg and the all-female CEO/R&D tandem at Acadia Pharmaceuticals.  

This episode reveals groundbreaking 2025 research that will revolutionize how you approach OMAD (One Meal A Day) fasting. Dr. Scott and Tommy break down a game-changing study showing how your pre-fast meal composition dramatically affects ketosis timing and fat burning efficiency during 24-hour fasts. Discover the shocking difference between starting a fast with a low-carb, high-fat meal versus a high-carb, low-fat meal: the low-carb group reached nutritional ketosis by hour 12, while the high-carb group never achieved ketosis during the entire 24-hour period. Learn how the right pre-fast meal drops insulin by 42% within one hour, increases fat-burning hormone glucagon by 24%, and naturally boosts GLP-1 (the "Ozempic hormone") by 27% and GIP by 34.5% - giving you natural appetite suppression and metabolic enhancement. The hosts explain why this simple meal composition change (60% fat, 30% protein, 10% carbs versus the opposite) can be the difference between plateau frustration and consistent fat loss results. Understand why your dinner OMAD might be sabotaging your progress, how meal timing amplifies these effects, and practical food swaps to optimize your pre-fast nutrition. If you're stuck in the 3-5 pound weight fluctuation cycle despite consistent OMAD fasting, this episode provides the missing piece to unlock sustained ketosis and accelerated fat burning. Essential listening for anyone wanting to maximize their OMAD strategy and achieve consistent, sustainable results without longer fasts or extreme measures. ⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠ Resources and Downloads: ⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠ ⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠ ⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠ ⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠ ⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠ Partner Links: Get your⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠ here!⁠⁠⁠ Get ⁠⁠⁠30% off a Keto-Mojo⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠Click here!⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠Fasting For Life Community⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://pmc.ncbi.nlm.nih.gov/articles/PMC11998415/pdf/12986_2025_Article_920.pdf

In this episode of The Common Sense MD, Dr. Tom Rogers dives into the revolutionary practice of microdosing GLP-1 medications, a class of drugs originally developed for diabetes but now widely recognized for their impressive benefits in weight loss, metabolic health, and beyond. Dr. Rogers shares his own experience with microdosing tirzepatide—even though he isn't diabetic or obese—and discusses why these medications are game-changers not just for diabetes and obesity, but for a wide array of health issues.He breaks down how GLP-1 and GIP incretin hormones work, the evolution of these medications, and what makes microdosing effective and accessible for more people. Dr. Rogers also covers the many potential off-label benefits: from cardiovascular and neuroprotective effects, to improved liver function, help with conditions like PCOS and migraines, addiction support, and more. He addresses the cost and accessibility of these drugs, especially through compounding pharmacies, and emphasizes safety, monitoring, and individualized care.Whether you're a patient interested in the latest in metabolic medicine or just curious about GLP-1s, this episode offers a clear, practical, and insightful look at how these medications can fit into a broader strategy for health, longevity, and well-being.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today we're diving into a topic that's been everywhere lately: GLP-1 medications like semaglutide and tirzepatide for weight loss. You may know them by names like Wegovy, Ozempic, Mounjaro, or Zepbound. I want to give you a clear, realistic picture of what to expect—because while the media loves to highlight the dramatic before-and-after photos, the real journey can be slower and more nuanced for some. So in this episode, we're going to talk about the truth—what these medications can do, what they can't, how long things really take, and what you need to know to set yourself up for success. Not hype, not magic promises—just real, honest insight to help you understand the process. Let's get into it. How GLP-1 & GIP/GLP-1 Agonists Work So first things first—how do these meds work? Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Basically, they mimic natural hormones in your body that help regulate blood sugar, slow digestion, and—most importantly for weight loss—reduce appetite and improve satiety. That means you feel fuller faster and stay full longer. You're not obsessing over food like before. And that's powerful. But—and this is a big one— these peptides don't magically erase years of weight gain overnight. What they do is help make weight loss easier by reducing hunger and supporting your metabolism—but they don't do all the work for you. It's important to remember they're a powerful tool, not a replacement for your efforts. You're still in control of your choices, habits, and long-term success. Why We Titrate the Dose—and What "Therapeutic Dose" Means Now, let's talk about dosing. When you start Wegovy, you don't start at the highest dose. It's gradually increased over several weeks to give your body time to adjust and to help reduce side effects like nausea or stomach upset. The usual schedule looks like this: You'll start with 0.25 mg once a week for the first month. Then it increases every four weeks—0.5 mg, then 1 mg, then 1.7 mg. By week 17, most people reach the full dose of 2.4 mg once a week—that's the dose shown in studies to lead to the most consistent weight loss, with many people losing around 15% of their total body weight over about a year. But here's the thing—not everyone follows this path exactly, and that's okay. Some people need to slow down or stay longer at a lower dose if they're having side effects. Others may need to increase sooner if they're not seeing appetite changes and are tolerating the medication well. And even though 2.4 mg is considered the “therapeutic dose,” not everyone needs to reach it. Some people feel great and lose weight at a lower dose—and if that's you, that's your sweet spot. The real goal is to find the lowest effective dose that controls your hunger, helps you lose weight at a steady pace, and keeps side effects to a minimum. This isn't a one-size-fits-all journey, and pushing through side effects just to hit the max dose isn't necessary—or safe. Your best dose is the one your body handles well and helps you make progress. *How Much Weight Can You Expect to Lose—and How Fast? Let's take a look at the clinical studies. In large trials, people on semaglutide lost about 15% of their total body weight over 68 weeks. For tirzepatide, it was even higher—20% or more in some cases. But here's the thing—those results happened over a year to a year and a half. Not 6 weeks. Not 3 months. It's a marathon, not a sprint. Also, most of the weight loss doesn't happen during the titration phase. You may see some weight loss early on, especially if your appetite plummets. But the bulk of the weight loss happens once you reach and maintain your therapeutic dose. Why Everyone's Journey Looks Different I can't stress this enough—everybody's journey is different. Some people feel zero hunger from their very first injection. Others don't notice a big change until week 10 or 12. Some drop 10 pounds in the first month. Others lose two pounds and feel discouraged. All of those experiences are normal. Your age, hormones, medications, stress levels, sleep, and past diet history? They all play a role. And let's be real—gaining 20, 50, or 100 pounds didn't happen in a few weeks, right? It likely took months or even years of lifestyle habits, hormonal shifts, emotional eating, or underlying conditions. So we have to give ourselves that same grace and patience when we're trying to take the weight off—even with medical support. Navigating Side Effects and Setbacks Let's talk about the side effects. Nausea, constipation, acid reflux, bloating—yeah, these are pretty common as your body adjusts. And sometimes, those symptoms are your body's way of saying: Hey, slow down. Pushing through intense side effects just to hit a higher dose isn't the goal. In fact, it's not safe. You want the lowest effective dose that keeps your appetite under control, the weight coming off gradually, and your side effects minimal or nonexistent. If you need to pause treatment to let your gut settle or even go back down a dose, that's not failure. That's smart, safe self-care. We're in this for the long haul. Trial and Error with Food—and That's OK One part of this journey that catches people off guard is how sensitive your stomach becomes—especially to certain foods or drinks. Greasy or fried foods, spicy meals, carbonated drinks, alcohol—these can all be triggers for nausea or even vomiting while you're on this medication.  And it makes sense when you think about it: the medication slows down how quickly food and drink leave your stomach. So if you're eating or drinking things that already tend to irritate the stomach lining, the effects can hit harder and last longer. Even if those foods didn't bother you before starting treatment, they might now. It's just one of those things your body has to adjust to, and it may take some trial and error to figure out what still works for you. What is Healthy, Sustainable Weight Loss? So what's a healthy pace of weight loss? In general, 1 to 2 pounds per week is considered safe and sustainable. But on GLP-1s, that might vary. Some weeks you may lose 3 pounds. Some weeks, nothing. And guess what? That's normal. You're looking for overall downward trends, not perfection. The goal here is steady, sustainable fat loss—not dropping weight so quickly that you feel miserable, drained, or start losing muscle. Remember, we're not chasing “skinny”—we're aiming for strong, lean, energized, and healthy. And I know we've talked about this before, but it's worth repeating: exercise is not optional when you're on a GLP-1. It's a must. When you lose weight, you lose both fat and muscle. If you're not actively working to maintain or build muscle, you risk becoming weaker and slowing down your metabolism in the process. We want to keep the muscle you have—and ideally, build more—so your body stays strong and your results last. What Is a “Non-Responder”? Now let's touch on something important: what if the medication doesn't seem to work? Let's talk about what it means to be a “non-responder” on a GLP-1 medication like Wegovy or Zepbound. In clinical terms, a non-responder is someone who has been on their therapeutic dose for at least 3 months and has lost less than 5% of their total body weight—even though they're taking the medication correctly and making lifestyle changes like adjusting their diet, increasing physical activity, and managing stress or sleep. Let's break that down with an example: If someone weighs 200 pounds, 5% of their total body weight would be 10 pounds. So if they've been on their therapeutic dose for 12 weeks and have only lost, say, 4 or 5 pounds—despite doing everything right—they may be considered a non-responder. But as we mentioned before, everyone's therapeutic dose may be different. The therapeutic dose isn't just the maximum dose like 2.4 mg of semaglutide or 15 mg of tirzepatide. It's the dose at which you personally begin to experience consistent appetite suppression, weight loss, and minimal side effects. For some people, that may happen at 1 mg of semaglutide. Others may not feel much of a difference until they reach the full 2.4 mg. Some may even respond better at 1.7 mg and not tolerate the higher dose at all. That's why we titrate slowly, monitor your symptoms, and assess both how you feel and how your body is responding. So how do we know if you've reached your therapeutic dose? We look at things like: Has your appetite significantly decreased? Are you noticing earlier fullness or fewer cravings? Are you losing weight consistently over time Are side effects tolerable or nonexistent? If the answer is yes, you're probably at your therapeutic dose. But if the answer is no—if your hunger hasn't changed much, the scale hasn't moved, and you're not noticing any shift in your eating patterns after 3 months on a stable, higher dose—it might be time to re-evaluate. That could mean adjusting the dose, checking for other health issues that might be interfering (like thyroid problems or certain medications), or even considering a different treatment approach. *So what are my final thoughts?  Your journey is unique. Not everyone responds the same way, and that's okay. The key is finding what works for your body, not just what the label says. These medications can absolutely change lives. But they're not magic. They work with your efforts—not instead of them. You'll need to be patient, flexible, and kind to yourself along the way. You may need to tweak your dose, change your food choices, or give your body time to adjust. That's part of the process. And remember—this isn't just about weight loss. It's about reclaiming your health, confidence, and energy. So take it one step at a time. Celebrate every win. And know that slow progress is still progress. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, be patient, and keep showing up for yourself. And as always, have a happy, healthy week.

“Obesity Rx

Have a comment? I'd love to hear from you! THE MATURE MUSCLE PODCAST - Season 4 / Episode 9: OZEMPIC, MOUNJARO & WEGOVY(SEMAGLUTIDE & TIRZEPATIDE)PLUS THE “NEW” WONDERS OF CREATINE MONOHYDRATEToday we had a chat about the huge increase in people using Mounjaro, Wegovy, and Ozempic . They all injectable medications that contain a glucagon-like peptide 1 (GLP-1) receptor agonist. This type of medication can treat obesity and manage blood sugar levels. Mounjaro is also a dual agonist, which means it mimics another hormone as well as GLP-1, this other hormone is GIP (glucose-dependent insulinotropic polypeptide).Mounjaro and Wegovy are injections that mimic hormones which send signals to the parts of your brain responsible for appetite and hunger. Wegovy and Mounjaro can help you feel fuller for longer and slow the emptying of your stomach, Mounjaro's GIP in addition to this helps with weight management by preventing fat from building up. Ozempic, containing GLP-1 has been clinically approved to treat diabetes and helps to regulate blood sugar.Creatine monohydrate is one of the most well-researched and effective supplements out there. It's best known for helping people build strength, muscle, and recover faster from exercise. Recent research also shows it can be helpful as we age—especially when combined with strength training—by supporting muscle and bone health. It may also give the brain a small boost, improving memory and mental sharpness in some people, especially older adults. New studies suggest it could help the heart and blood vessels, and even support mood and mental health, though more research is needed in those areas. Overall, it's a safe and affordable supplement with a wide range of benefits beyond just gym performance.I hope you find this useful and enjoyed the podcast. Watch for the next episode soon, please subscribe when you can and please leave us a rating or review. Click the link highlighted to find out more about Lee here.Please also join the Mature Muscle Podcast Facebook Group for the latest info.

Today's episode dives into Retatrutide—the upcoming “Triple G” weight loss medication creating major buzz. Dr. Lisa shares the science behind this powerful GLP-1 / GIP / glucagon receptor agonist, explains why it's being called the “Taylor Swift of meds,” and answers common questions from a recent women's summer event. From dramatic weight loss results to calming relentless food noise, we explore why Retatrutide may redefine obesity treatment—and why support, not just medication, is key for long-term health, longevity, and weight loss success. Whether you're on a weight loss med, considering one, or just curious, this episode gives you the scoop you'll want before everyone else is talking about it.If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

In recent years, the fitness industry has witnessed a notable surge in the utilization of GLP-1 and now also GIP agonists, as a novel approach to enhance weight loss outcomes.In today episode I'm revisiting the topic (I did another episode on GLP-1s in Season 2, you can find that episode HERE) of GLP-1s. I will be discussing:The surprising usage statistics and rapid increase in prevalence of this drug classThe widespread misuse, and over prescription of this drugWhat the use of these drugs says about how society views the obesity epidemicHow GLP-1 impacts motility in the GI tract and those long term consequenceswho might benefit most from these medications, versus who should steer clear My personal thoughts  __________________________________________Join me on the 'gram! Get free recipes and tips delivered right to your inbox every Friday!Learn more about your options for working 1:1 with me: https://www.revivewellness.health/services Schedule a free call with me hereTry Syntrax! To try to the most delicious, gluten free, lactose free "top of the line" whey isolate AND save 25% use the code "syntraxallison" at checkout.Want some FREE LMNT? Use this link for a FREE sample pack with any order!Better Bodies discount code "BB15" at checkout to save 15% on my favorite betterbodies gear! Save 10% on PureFactorFormulations supplements with my code "Revive10" at checkout!

The words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology's annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech's solid tumor bispecific BNT327. Elsewhere, Sanofi nabbed the year's second-biggest buyout, picking up Blueprint for $9.5 billion, expanding its rare disease portfolio. And Regeneron plunked down up to $2 billion to license a dual GLP-1/GIP receptor agonist from Chinese biopharma Hansoh Pharmaceuticals Group.  Back in Chicago, presentations by AstraZeneca, Gilead and Amgen drew rave reviews from investor analysts, while Pfizer and Arvinas elaborated on mixed data from a PROTAC that showed positive results in only a subsection of breast cancer patients, failing to impress Wall Street. Meanwhile, Bicara's solid survival stats in head and neck cancer weren't enough to clear the high bar set by rival Merus. At the meeting, BioSpace's own Dan Samorodnitsky sat down with Jazz Pharmaceuticals' CMO Rob Iannone to discuss the company's recently acquired pediatric glioma drug, and talked AI strategy with AstraZeneca's head of U.S. oncology for lung cancer Arun Krishna. Dan recaps his ASCO experience here.  Speaking of buzzy therapeutic spaces, there was more action on the vaccines front last week as Health and Human Services Secretary RFK Jr. announced that healthy children and healthy pregnant women would no longer be advised to get vaccinated against COVID-19. However, as of publication, the CDC still recommends a COVID vaccine for healthy children but instead of a universal recommendation advises that the decision should be made between parents and healthcare providers. Against this backdrop, the FDA signed off on Moderna's next-gen COVID-19 vaccine, mNEXSPIKE, for a limited population in line with its new guidelines. This was a much-needed win for Moderna, which last week had a $760 million-plus government contract for its mRNA-based bird flu vaccine terminated.  Also on the policy front, the Trump administration released its Make America Healthy Again report last week to much scrutiny after reports found studies and references that did not exist.  

Mayo ya se va. Y lo sobrevolamos recordando algunas de las novedades favoritas que te hemos presentado a lo largo del mes.(Foto del podcast; Private Function)Playlist;(sintonía) LOST ACAPULCO “México libre” (Death by robots)PRIVATE FUNCTION “Gamma Ray” (A bunch of songs)SPLIT SYSTEM “Quemicals”CYANIDE PILLS “Falling for you”NERVOUS EATERS “No more idols”THE SOUND MINDS “Hide and seek”THE UNTAMED YOUTH “Patty baby” (Gip up and go!)BILLY CHILDISH and THE CHATHAM SINGERS “Beneath the midnight trees” (Step out!)VINICIUS e SEU CONJUNTO SALVAGEM “Vou roubar o seu corasao”BLOODSHOT BILL “Rule book”LOS TORONTOS “Take a bath”LOS MEJILLONES TIGRE “Vente conmigo (el baile del vampiro)” (Me gustó más el libro)GARBAYO “Corre conmigo” (Días de euforia)TY SEGALL “Possession” (Possession)ROBERT FORSTER “All of the time” (Strawberries)ANGELA HOODOO “Fugitivo” (Outlaw girls)JODIE CASH “That light on me” (My senses)NEIL YOUNG and THE CHROME HEARTS “Talkin’ to the trees”Escuchar audio

Jordan Kimler, Nurse Practitioner with Premier U, joined us again in studio, to give us updates on Heidi's weight loss journey, and the difference between GLP-1 and GIP.

Summary In this episode of the Future of Dermatology podcast, Sam Kamangar asks Dr. Faranak Kamangar your burning questions about GLP-1 and GIP medications. They discuss the evolving landscape of dermatology, explore the implications of these medications for weight loss, metabolism, and skin health, as well as the aesthetic considerations and potential side effects associated with their use. The episode emphasizes the importance of understanding who qualifies for these medications and the need for a holistic approach to health and beauty. Takeaways - The conversation around beauty is shifting from surface-level treatments to internal health. - GLP-1 medications are gaining popularity for their weight loss benefits. - FDA-approved medications undergo rigorous testing for safety and efficacy. - Weight loss is a chronic condition that requires ongoing management. - Muscle mass is crucial for maintaining metabolism as we age. - GLP-1 medications can have side effects, including gastrointestinal issues. - Hydration and diet play significant roles in managing side effects of GLP-1 medications. - Aesthetic concerns, such as 'Ozempic face,' are emerging with the use of GLP-1 medications. - Not everyone needs to be on GLP-1 medications; they are for those with obesity or diabetes. - The hype around GLP-1 medications may lead to overuse and shortages for those who truly need them. Chapters 00:00 - Introduction to Dermatology and GLP-1 Medications 03:04 - Understanding GLP-1 and GIP Medications 05:57 - The Role of GLP-1 in Dermatology 08:55 - Who Should Use GLP-1 Medications? 11:59 - Metabolism and Chronic Conditions 14:58 - The Hype Around GLP-1 Medications 17:59 - Aesthetic Considerations with GLP-1 Use 20:49 - Managing Side Effects of GLP-1 Medications

Did you know that some weight loss medications can help people lose up to 20% of their body weight, comparable to bariatric surgery outcomes? In this episode, I dive into the latest research comparing two major weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide), based on findings from the 72-week SURMOUNT-5 trial. I explain how Zepbound led to greater weight loss (about 20.2% vs. 13.7% with Wegovy), possibly due to its dual action on GIP and GLP-1 receptors. Both drugs were generally well tolerated, with similar side effects like nausea and constipation, though Wegovy had slightly more people stop due to GI issues. I also emphasize that while Zepbound may appear more effective, individual needs, such as cardiovascular health or sleep apnea, should guide treatment decisions. Lastly, I remind you that sustainable weight loss requires patience, realistic expectations, and a holistic approach that includes lifestyle changes, not just medication. Tune in to this episode to learn which weight loss medication might be right for you and why your journey to health is more than just the number on the scale.   Episode Highlights: Comparison of Wegovy (semaglutide) and Zepbound (tirzepatide) Average weight loss outcomes and waist circumference changes between both medications Mechanism of action: GLP-1 vs. dual GIP/GLP-1 receptor targeting Side effect profiles and tolerability of both medications FDA approval differences, including cardiovascular risk reduction and sleep apnea treatment Importance of personalized treatment plans and setting realistic weight loss expectations Ongoing research into oral formulations and long-term safety studies Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Such a fascinating and jam-packed conversation with my guy - Calvin Scheller. Calvin has a real talent for breaking down complex science + together we dive into what actually influences our appetite. Topics discussed:-What drives people to eat?-How environment, psychology, and physiology influence what (and how much) we eat.-Defining appetite: what it actually means.-The role of the hypothalamus and brain in assessing our body's needs.-Orexigenic vs. anorexigenic signaling (aka the signals that drive us to eat more or less).-Hormones you've probably heard of - cortisol, serotonin, and dopamine & how they impact hunger.-A deep dive into leptin: what it is, how it works, and what leptin resistance means.-Why people with higher body fat levels might actually experience more hunger, not less.-GLP-1 and GIP: their role in appetite suppression and a discussion around common weight loss medications.+ so much more in-between. I loved this chat + I know you will too!Where to find Calvin: IG: @calvin_schellerTikTok: @physiologywithcalvinCheck out Calvin's Coaching HEREWhere to find me: IG: @lukesmithrdCheck out my website HERETIA for listening!!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. It's an exciting time to be practicing in obesity medicine, with groundbreaking tools like Zepbound and Wegovy helping people achieve their weight loss goals in ways that were once unimaginable. Plus, with new medications like retatrutide (the triple agonists) on the horizon, the future of weight management is looking even brighter.But with so many options available, it can be overwhelming to figure out which medication is right for you. How do Zepbound and Wegovy compare? Can you switch between the two? Is one more effective than the other? In this episode, I'll dive into the key differences between Zepbound (Mounjaro) and Wegovy (Ozempic), comparing doses, effectiveness, and answering all your burning questions about how these medications stack up against each other. ReferencesThe Top 5 Mistakes People Make When Starting GLP-1 Season 1 of the Premium Podcast: The Obesity Guide: Behind the CurtainAudio Stamps00:30 - Dr. Rentea sets the stage for a back-to-basics breakdown of Wegovy vs. Zepbound, which touches on key topics like switching, dosing, and access.01:58 - A comparison of Wegovy (GLP-1) and Zepbound (dual GLP-1 and GIP), discussing their average weight loss effects and varying response rates.05:19 - Dr. Rentea discusses the reasons someone might consider switching medications.06:45 - Switching medications shouldn't involve restarting titration, and working with a knowledgeable physician to manage transitions effectively is key.11:45 - Medication can be a helpful tool, but long-term success depends on working with a skilled physician and staying focused on sustainable progress.Quotes“Within the first few months, it's going to become very clear. Do you need an additional tool? Do we need to tweak things? Do we need to change things?”“These are medications, but they're not everything. You still have to do the heavy lifting on the lifestyle aspect behind the scenes. But you have the ability to switch from one to the other.”“You really should be working with someone who is very familiar with these medications, with switching medications, with adding other things to it, with changing things. There is always something else that can be done.”“We do sometimes see higher results with ZepBound, but there's going to be other medication that comes out that's potentially higher than that. At the end of the day, it's what helps me to keep doing all the other things.”All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.

In this first part of a two-part series, Dr. Saluja and Kane unpack how GLP-1 and GIP medications, including Ozempic, Wegovy, and Mounjaro, are reshaping not just metabolism, but also facial structure, leading to what's now known as "Ozempic Face." In this episode, they explore what GLP-1 receptor agonists and GIP agonists are, how rapid fat loss affects skin, collagen, and volume, and introduce key strategies that can be done at home from a nutritional perspective to support collagen health and overall facial balance. Join them as they break down the science and lay the foundation for more advanced treatment approaches discussed in Part Two. Thank you for your listenership!

Summary Join Dr. Faranak Kamangar as she embarks on the podcast journey of dermatometabolics. For the next few weeks she'll explore various topics in the realm of dermatometabolics such as insulin resistance, GLP and GIP, and skin care. Stay tuned!

So, you've heard the rumors—“GLP-1s destroy your muscle!” But… is that actually true? Think again. Today, we're setting the record straight. If you're serious about real, healthy weight loss—and actually keeping your strength for the long haul—this episode is a must. We're diving into a long-overdue conversation about GLP-1 medications, metabolism, body composition, and what's really happening to your muscle mass on these meds. Because weight loss isn't just about the scale—it's about how you lose it. Let's get into it. Quick Basics — What Are GLP-1 and GIP/GLP-1 Medications? Let's start at ground zero. GLP-1 medications — like semaglutide (Wegovy and Ozempic) — are game-changers for weight loss and diabetes. They work by mimicking gut hormones that regulate appetite, blood sugar, and insulin release. GLP-1 (glucagon-like peptide 1) slows down how fast your stomach empties, helps your body respond better to insulin, and most importantly — makes you feel fuller, longer. Tirzepatide (Mounjaro and Zepbound), also hits GIP receptors — that's glucose-dependent insulinotropic polypeptide — lending to more blood sugar regulation in some people. What Happens to Your Body During Weight Loss? No matter how you lose weight — whether it's from keto, bariatric surgery, or GLP-1 meds — your body isn't just burning fat. It's normal to lose a mix of fat mass and lean mass, which includes muscle, bone, and organ tissue. But the goal with any good weight loss plan is to maximize fat loss and minimize muscle loss. The Myth: “GLP-1s Make You Lose All Your Muscle” Here's the truth: GLP-1 medications do NOT inherently destroy your muscle mass. In fact, clinical studies have shown that GLP-1 medications, like semaglutide, have osteoblastic effects, meaning they can stimulate the activity of osteoblasts, the cells responsible for bone formation. This can potentially help improve bone density and support bone health. While the primary role of GLP-1 medications is to aid in weight loss and improve blood sugar control, these osteoblastic effects may offer additional benefits, especially in individuals at risk for osteoporosis or bone loss. If you see muscle loss during GLP-1 therapy, it's because of rapid overall weight loss and a lack of resistance training and protein — not because the medication is wasting your muscle. It's the same thing we see in ANY rapid weight loss — if you don't stimulate your muscles and feed them the right building blocks, your body gets rid of them because it thinks you don't need them. Muscle is metabolically expensive. Your body is smart — if it thinks you're not using muscle, it's going to save energy and dump it. That's biology — not the medication. Why Protein and Resistance Training Are Non-Negotiable If you're on a GLP-1, your appetite is lower — which is great for fat loss, but it means you could accidentally under-eat protein if you're not paying attention. Protein is literally the raw material your body uses to maintain and build muscle. Protein also helps build and repair tissues and is essential for producing enzymes, hormones, and maintaining a healthy immune system. Without enough, your body will start to break down lean tissue to make up the difference. And without resistance training (e.g., bodyweight exercises), your body assumes you don't need the muscle anymore. Use it or lose it. How to Protect (and Even Build) Muscle on GLP-1s Here's the simple formula: Prioritize protein: Aim for at least 0.8 to 1 grams per pound of body weight per day. Some need even more during active fat loss. Strength train 2–4 times a week: Focus on compound movements — think squats, deadlifts, presses, pulls, push ups, lunges, planks, and wall sits. Don't fear the scale: Remember that as you lose fat and build muscle, the number might not drop as fast — but your body composition is improving (e.g., reduced body fat, more defined muscles, improved waist circumference, increased energy and strength, and don't forget improved cardiovascular health). Think long-term: It's not just about losing weight — it's about keeping a strong, healthy, metabolically active body. THIS is what helps maintain weight loss. Making sustainable lifestyle changes can be challenging, but they are the most important choice you can make when it comes to losing weight and improving your metabolism in the long run. The goal isn't just weight loss — it's fat loss while preserving and strengthening lean mass. It's important to remember that GLP-1s are a powerful tool, but they aren't a magic. You still have to partner with your body — feed it well, move it wisely, and respect the incredible machine it is. Strong, lean, metabolically active — that's the future we're building, not just smaller bodies. Thanks again for listening to The Peptide Podcast. If this episode helped you rethink your game plan, do me a favor — share it with someone who's starting their GLP-1 journey. And as always, have a happy healthy week! Thanks for listening to The Peptide Podcast. If you found this episode helpful, please follow or leave a review. And if there's a topic you'd like to hear more about, feel free to reach out—we'd love to hear from you. As always, have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

This week's expert, Hepatologist and Key Opinion Leader Mazen Noureddin, joins Roger to discuss major advances in drug development over the past year. He covers a range of different drug classes, focusing on stages of development and the range of options within each class. First, Mazen discusses a tremendously exciting group of FGF-21 agents, specifically mentioning Akero Therapeutics's efruxifermin, 89bio's pegozafermin, and Boston Pharmaceuticals's efimosfermin. He points to efruxifermin's 96-week results to suggest that FGF-21s might be appropriate for a wide range of patients, the idea that the drug's duration of effect may make the idea of “induction therapy” less appropriate, and the exciting early data on cirrhosis patients. He also mentions pegozafermin's publication of data in the New England Journal of Medicine and efimosfermin's promising data based on monthly dosing. Next, Mazen provides some detail on the various incretin agonist options, why hepatologists are particularly excited about combinations that include a glucagon agent, and what kinds of results we might expect in upcoming trials. Finally, Mazen discusses other promising compounds in later-stage development, including the pan-PPAR lanifibranor and the FASN inhibitor denifenstat. He notes ongoing work on new classes and combination therapies. 

According to the Centers for Disease Control and Prevention, more than 40% of American adults have obesity, costing the U.S. healthcare system an estimated $173 billion annually. The development of incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), marks a major advance in obesity treatment. Registered Dietitian Nutritionists (RDNs) play a crucial role in providing medical nutrition therapy (MNT) to people using these medications as part of comprehensive obesity care. Tune into this episode to learn about: ●       the new paper published in JAND about injectable weight loss medications and lifestyle interventions ●       the unique and evolving role of RDNs in obesity care ●       why this new class of obesity medications has become so popular ●       how these medications work ●       the amount of weight loss needed to reduce obesity related comorbidities ●       the evolution of different terms for these medications ●       the pipeline of obesity medications we will see in the next few years ●       how these medications have impacted the role of RDNs in counseling patients ●       common side effects and nutritional considerations ●       concerns about loss of muscle mass and bone density ●       the importance of and role of exercise while taking these medications ●       emotional aspects of significant weight loss in a short time ●       how RDNs can be utilized in comprehensive obesity care in the long term ●       how RDNs can stay informed and up to date on the medications and obesity care in general ●       when people taking these medications should be referred to RDNs ●       how working with an RDN can improve a person's experience and outcomes ●       additional information and resources for the public and health professionals Full shownotes, transcript and resources: https://soundbitesrd.com/284          

TOPICS:⁃ WHAT IS GLP-1 & GIP? WHAT ARE THE MECHANISMS BY WHICH THEY HELP WITH WEIGHT LOSS?⁃ CAN WE GO OVER THE CURRENT ANTI-OBESITY MEDICATIONS AVAILABLE AS WELL AS THE ONES THAT WILL BE RELEASED WITHIN THE NEXT FEW YEARS⁃ LIRAGLUTIDE⁃ SEMAGLUTIDE⁃ TIRZEPATIDE⁃ RETRATUTIDE⁃ CAGRISEMA⁃ BIMAGRUMAB⁃ SEX DIFFERENCES IN RESPONSE TO GLP-1 RA'S⁃ WHY WOMEN LOSE FASTER & MORE WEIGHT ON GLP-1'S⁃ WHAT ARE THE MOST COMMON MISTAKES PEOPLE MAKE WHEN USING THESE COMPOUNDS?⁃ HOW TO OPTIMIZE BODY COMPOSITION OUTCOMES WHEN USING GLP-1'S?⁃ WHAT STRATEGIES CAN BE USED TO KEEP THE DOSE LOWER TO KEEP SIDE EFFECTS LOWER?⁃ FAT & WEIGHT LOSS PLATEAUS⁃ WHAT TO DO IF SOMEONE WANTS TO COME OFF? TAPERING OFF GLP'SWHERE TO CONNECT WITH ME:Follow Brandon on IG: https://www.instagram.com/brandondacruz_/Email: Bdacruzfitness@gmail.comFor Info on Brandon's Coaching, Consultation & Mentorship Services: https://form.jotform.com/bdacruzfitness/coachinginquiryBrandon's Website: https://www.brandondacruzfit.comLink To Lyle's New Book: https://www.amazon.com/dp/B0DT26F7HY

In this Metabolic Classroom lecture, Dr. Bikman explores GLP-1 receptor agonists (such as Ozempic and Mounjaro) and how to use them more effectively.Ben first explains how GLP-1 is naturally produced in the gut and helps regulate glucagon suppression, slows gastric emptying, and promotes satiety. However, he highlights research showing that individuals with obesity have a blunted GLP-1 response to carbohydrates, which may contribute to overeating. He suggests that GLP-1 drugs could be used more strategically—not just for general weight loss, but specifically to control carbohydrate cravings.While these drugs can promote rapid weight loss, they can also come with serious trade-offs, including mental health risks (depression, anxiety, and suicidal thoughts), lean mass loss (up to 40% of weight lost), diminishing effects over time, and digestive complications such as gastroparesis (stomach paralysis). He critiques the current high-dose, long-term approach to these medications, arguing that most people are not using them strategically and eventually regain lost weight—primarily as fat.Dr. Bikman proposes a better approach to using GLP-1 drugs that focuses on low-dose, short-term usage to help control carbohydrate cravings, rather than suppressing appetite completely.His four-step plan includes: (1) starting at the lowest effective dose, (2) engaging in resistance training to preserve muscle mass, (3) adopting a low-carb, high-protein diet, and (4) cycling off the drug after 3-6 months to assess whether cravings remain under control. He also discusses newer GLP-1/GIP dual agonists like Tirzepatide, which may be even more effective but still require careful usage.In closing, Ben emphasizes that GLP-1 drugs should be a tool, not a crutch.The ultimate goal should be to regain control over eating habits, build long-term dietary discipline, and use the drug only when needed. He encourages those considering these medications to work closely with their healthcare providers and approach them with a long-term metabolic health strategy in mind.Show Notes/References:For complete show notes and references referred to in this episode, we invite you to become a Ben Bikman Insider subscriber. As a subscriber, you'll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben, ad-free Metabolic Classroom Podcast episodes, show notes and references, Ben's Research Reviews Podcast, and a searchable archive that includes all Metabolic Classroom episodes and Research Reviews. Learn more: https://www.benbikman.com Hosted on Acast. See acast.com/privacy for more information.

On this episode of the Top 200 Drugs podcast from Real Life Pharmacology, we cover Percocet, Epogen, quetiapine, glimepiride, and tirzepatide. These are drugs 166-170. Percocet is a combination analgesic. It contains acetaminophen and oxycodone. Pay attention to acetaminophen intake from all sources when patients are on this medication. Epogen (epoetin alfa) stimulates the production of red blood cells. This medication can be useful in treating anemia. Quetiapine (Seroquel) is an antipsychotic. It is often used in patients with hallucinations and delusions associated with Parkinson's disease because it has a lower potential to block dopamine receptors compared to other antipsychotics. Glimepiride is a sulfonylurea. This medication stimulates the release of insulin which can help lower blood sugars in diabetes. Tirzepatide (Mounjaro) is a combination GIP and GLP-1 receptor agonist that can be used for weight loss and the treatment of diabetes.

*TW - Suicide and disordered eating are both briefly mentioned in this episode. Dr. Marguerite Germain is our esteemed guest. She is a board-certified dermatologist and one of the foremost experts in both medical dermatology and aesthetic medicine. Based in Charleston, South Carolina, where she's been voted Best Dermatologist for an incredible 20 consecutive years. She shares with us her personal opinions and medical expertise on topics such as how trauma, stress, hormones, autoimmune disease, viruses (such as COVID) and use of GLP-1 & GIP medications (such as Ozempic, Weygovy, & Mounjaro) can contribute to a decrease in hair & scalp health, skin disease and even nail health. She also shares solutions of how to better care for your hair, skin & nails and support overall health. Visit www.germaindermatology.com to learn more about her practice and shop for products. You can use code GIN20 for a 20% discount on Xtressé - the gummy that supports hair and scalp health. Follow on INSTAGRAM. ______________________________________________________________ We LOVE collecting 5 stars -- Don't forget to follow, leave a review or rating and share Drinking With Gin.